Efalizumab (Raptiva) has been filed for the treatment of moderate-to-severe psoriasis in the US. Earlier this year, the FDA had requested that a third Phase III trial be conducted after conflicting results from a pharmacokinetic study. The current study included 556 patients with moderate-to-severe plaque psoriasis who received either Raptiva or placebo in the form of a subcutaneous injection for 12 weeks. The trial aimed to establish the proportion of patients who achieved 75% or greater improvement in the PASI 75 index (a measure of psoriasis severity). The companies (Genentech and Xoma) say the results are positive and the full data will be presented at a future meeting. European partner Serono plans to file for European marketing clearance during the first quarter of 2003.
Source: PharmaTimes News (link)
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!